Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
| NCT ID | Title | Phase | Status | Enrollment | Velocity | Design | Start | Completion | Last Updated | Sites | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|
| NCT01033396 | The Effect Of PF-03654764 +/- Allegra On Symptoms Of Allergic Rhinitis | PHASE2 | COMPLETED | 64 | — | — | Jan 1, 2010 | May 1, 2010 | Aug 17, 2010 | 1 | Canada |
| Arm | Type | Description |
|---|---|---|
| PF-03654764 + Allegra | EXPERIMENTAL | - |
| PF-03654764 | EXPERIMENTAL | - |
| Allegra-D | ACTIVE_COMPARATOR | - |
| Placebo | PLACEBO_COMPARATOR | - |
| Name | Type | Description |
|---|---|---|
| PF-03654764 | DRUG | PF-03654764 single dose 5 mg |
| Allegra | DRUG | Fexofenadine single dose 60 mg |
| Allegra-D | DRUG | Fexofenadine 60 mg combined with pseudoephedrine 120 mg single dose |
| Placebo | DRUG | Placebo single dose |
Inclusion Criteria: * Male or female subjects 18-60 years allergic to ragweed pollen. * Subjects with appropriate symptom scores following exposure to ragweed in the environmental exposure unit. Exclusion Criteria: * Subjects with significant diseases other than allergic rhinitis that may interfe...
| Company | Ticker | Trials | Lead Phase | Drugs |
|---|---|---|---|---|
| Eli Lilly and Company | LLY | 1 | PHASE3 | LY3650150, Standard therapy for INCS |
| Polyrizon Ltd. | PLRZ | 1 | NA | Undisclosed |
| Regeneron Pharmaceuticals, Inc. | REGN | 1 | — | Undisclosed |